RxDoctor Payments Data

Christina Henry, DO

Family Medicine · Las Vegas, NVNPI 1629412002

Payments from drug & device makers

$534in general payments, 2019–2025

Across 22 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$164
  • Novo Nordisk$104
  • Johnson & Johnson$98
  • Quidel Corporation$39
  • Abbott$25
  • Exact Sciences$19
  • plus $86 from 6 others

What the payments were for

  • Food & beverage$534100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca4$164
Novo Nordisk7$104
Johnson & Johnson1$98
Quidel Corporation2$39
Abbott1$25
Exact Sciences1$19
Antares Pharma, Inc.1$16
Neos Therapeutics, LP1$15
Boehringer Ingelheim1$15
Intuitive Surgical1$14
Metuchen Pharmaceuticals1$13
Nalpropion Pharmaceuticals LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$534 in reported general payments places this provider in the 55th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$6,940
Medicare patients
31
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$122,806
JardianceEmpagliflozin53$79,637
RybelsusSemaglutide40$58,180
TrulicityDulaglutide22$34,116
OzempicSemaglutide25$33,854
MounjaroTirzepatide17$30,130
XareltoRivaroxaban26$27,776
FarxigaDapagliflozin Propanediol20$27,102
JanuviaSitagliptin Phosphate22$26,048
TradjentaLinagliptin21$25,033
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$24,980
MyrbetriqMirabegron17$23,289
Breo ElliptaFluticasone/Vilanterol26$13,057
SymbicortBudesonide/Formoterol Fumarate25$9,943
Synjardy XrEmpagliflozin/Metformin Hcl12$8,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$15$112,69086 claims
Novo NordiskRybelsus, Ozempic$104$92,03465 claims
AstraZenecaFarxiga, Symbicort$164$37,04545 claims
Johnson & JohnsonXarelto$98$27,77626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →